Randomized Phase III trial of afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one prior trastuzumab treatment: LUX-Breast 1

被引：2

作者：

Harbeck, Nadia ^{[1
]}

Huang, Chiun-Sheng ^{[2
]}

Hurvitz, Sara ^{[3
]}

Yeh, Dah-Cherng ^{[4
]}

Shao, Zhimin ^{[5
]}

Im, Seock-Ah ^{[6
]}

Jung, Kyung Hae ^{[7
]}

Shen, Kunwei ^{[8
]}

Ro, Jungsil ^{[9
]}

Jassem, Jacek ^{[10
]}

Zhang, Qingyuan ^{[11
]}

Im, Young-Hyuck ^{[12
]}

Wojtukiewicz, Marek ^{[13
]}

Sun, Qiang ^{[14
]}

Chen, Shin-Cheh ^{[15
]}

Goeldner, Rainer-Georg ^{[16
]}

Lahogue, Annick ^{[17
]}

Uttenreuther-Fischer, Martina ^{[16
]}

Xu, Binghe ^{[18
]}

Piccart-Gebhart, Martine ^{[19
]}

机构：

[1] Univ Munich, Frauenklin, Brustzentrum, D-81377 Munich, Germany

[2] Natl Taiwan Univ Hosp, Taipei, Taiwan

[3] Univ Calif Los Angeles, David Geffen Sch Med, Translat Res Oncol, Los Angeles, CA 90024 USA

[4] Taichung Vet Gen Hosp, Taichung, Taiwan

[5] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[6] Seoul Natl Univ Hosp, Seoul, South Korea

[7] Univ Ulsan, Coll Med, Asan Med Ctr, Ulsan, South Korea

[8] Ruijin Hosp, Comprehens Breast Hlth Ctr, Shanghai, Peoples R China

[9] Natl Canc Ctr, Singapore, Singapore

[10] Med Univ Gdansk, Gdansk, Poland

[11] Harbin Med Univ, Affiliated Hosp 3, Harbin, Peoples R China

[12] Samsung Med Ctr, Seoul, South Korea

[13] Med Univ, Ctr Comprehens Canc, Gdansk, Poland

[14] Beijing Union Med Coll Hosp, Beijing, Peoples R China

[15] Chang Gung Med Fdn, Linkou Branch, Kaohsiung, Taiwan

[16] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[17] SCS Boehringer Ingelheim Comm V, Ingelheim, Germany

[18] Chinese Acad Med Sci, Cancer Inst & Hosp, Beijing, Peoples R China

[19] Inst Jules Bordet, Brussels, Belgium

来源：

CANCER RESEARCH | 2015年 / 75卷

关键词：

D O I：

10.1158/1538-7445.SABCS14-P5-19-01

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P5-19-01

引用

页数：2

共 50 条

[21] Trastuzumab plus intravenous or oral vinorelbine in chemonaive patients with HER-2 overexpressing metastatic breast cancer: Final results of an extended phase II trial
Bernardo, Giovanni
Palumbo, Raffaella
Bernardo, Antonio
Poggi, Guido
Delmonte, Angelo
Teragni, Cristina
Frascaroli, Mara
Jedrychowska, Ivona
Canto, Andrea M.
Strada, Maria Rosa
[J]. ANNALS OF ONCOLOGY, 2006, 17 : 76 - 76
[22] Final results of a phase II study of weekly trastuzumab and vinorelbine in chemonaive patients with HER2-overexpressing metastatic breast cancer.
Bernardo, G
Palumbo, R
Bernardo, A
Villani, G
Melazzini, M
Poggi, G
Frascaroli, M
Jedrychowska, I
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 59S - 59S
[23] Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
Cortes, Javier
Dieras, Veronique
Ro, Jungsil
Barriere, Jerome
Bachelot, Thomas
Hurvitz, Sara
Le Rhun, Emilie
Espie, Marc
Kim, Sung-Bae
Schneeweiss, Andreas
Sohn, Joo Hyuk
Nabholtz, Jean-Marc
Kellokumpu-Lehtinen, Pirkko-Liisa
Taguchi, Julie
Piacentini, Federico
Ciruelos, Eva
Bono, Petri
Ould-Kaci, Mahmoud
Roux, Flavien
Joensuu, Heikki
[J]. LANCET ONCOLOGY, 2015, 16 (16): : 1700 - 1710
[24] Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
Guy Jerusalem
Angelica Fasolo
Veronique Dieras
Fatima Cardoso
Jonas Bergh
Luc Vittori
Yufen Zhang
Cristian Massacesi
Tarek Sahmoud
Luca Gianni
[J]. Breast Cancer Research and Treatment, 2011, 125 : 447 - 455
[25] Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
Jerusalem, Guy
Fasolo, Angelica
Dieras, Veronique
Cardoso, Fatima
Bergh, Jonas
Vittori, Luc
Zhang, Yufen
Massacesi, Cristian
Sahmoud, Tarek
Gianni, Luca
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2011, 125 (02) : 447 - 455
[26] Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With HER2-Overexpressing Metastatic Breast Cancer
Yardley, Denise A.
Burris, Howard A., III
Hanson, Sarah
Greco, F. Anthony
Spigel, David R.
Barton, John
Hainsworth, John D.
[J]. CLINICAL BREAST CANCER, 2009, 9 (03) : 178 - 183
[27] THREE-WEEKLY TRASTUZUMAB PLUS VINORELBINE IN THE TREATMENT OF METASTATIC BREAST CANCER. A PHASE 2 STUDY
Pacilio, C.
De Maio, E.
Gravina, A.
Labonia, V.
Landi, G.
Nuzzo, F.
Rossi, E.
Silvestro, P.
Staiano, M.
La Vecchia, F.
Di Bonito, M.
Botti, G.
Thomas, R.
D'Aiuto, G.
Salzano, M. R.
Vallone, P.
Perrone, F.
de Matteis, A.
[J]. ANNALS OF ONCOLOGY, 2004, 15 : 21 - 21
[28] Randomized Phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib-based therapy: LUX-Breast 3
Cortes, Javier
Dieras, Veronique
Ro, Jungsil
Barriere, Jerome
Bachelot, Thomas
Hurvitz, Sara
Le Rhun, Emilie
Espie, Marc
Kim, Sung-Bae
Schneeweiss, Andreas
Sohn, Joo Hyuk
Nabholtz, Jean-Marc
Kellokumpu-Lehtinen, Pirkko-Liisa
Taguchi, Julie
Piacentini, Federico
Ciruelos, Eva
Bono, Petri
Ould-Kaci, Mahmoud
Roux, Flavien
Joensuu, Heikki
[J]. CANCER RESEARCH, 2015, 75
[29] High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer:: A phase II study
Stemmler, HJ
Kahlert, S
Brudler, O
Beha, M
Müller, S
Stauch, B
Heinemann, V
[J]. CLINICAL ONCOLOGY, 2005, 17 (08) : 630 - 635
[30] Trastuzumab (T) plus oral vinorelbine (OV) in patients with advanced breast cancer (ABC) overexpressing Her2/neu
不详
[J]. EJC SUPPLEMENTS, 2006, 4 (02): : 168 - 168

← 1 2 3 4 5 →